Insulinoma Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Insulinoma Treatment Market is segmented By Disease Type (Benign, Metastatic), By Treatment Type (Chemotherapy (Anti cytotoxic drugs (Doxorubicin, Fluorouracil, Etoposide, Others), Somatostatin Analogues (Octreotide, Lanreotide), Radiation Therapy (Stereotactic ablation radiation therapy (SABR), Selective internal radiation therapy (SIRT)), Surgeries, Others), By End User (Hospitals and Clinics, Cancer Research Centers and Institutes, Others, and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Insulinoma Treatment Market Size

Global Insulinoma Treatment Market reached US$ YY million in 2023 and is expected to reach US$ YY  million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Insulinomas are rare pancreatic endocrine tumors that can be benign or malignant. Only 10% of insulinomas are malignant. The main symptom is hypoglycemia, i.e., a decrease in blood sugar levels due to the oversecretion of insulin. Most insulinomas are non-cancerous. Hence, the drugs used are to decrease the amount of insulin secreted by islet cells in the pancreas.

Surgery is the primary treatment for insulinomas. However, somatostatin analogs such as octreotide and lanreotide are given to lower insulin levels. Nearly 5-12% of all insulinomas account for metastatic insulinomas. Once the metastasis spreads to lymph nodes or the liver, the survival span is about two years.

Insulinoma Treatment Market Scope

For more details on this report Request for Sample

Insulinoma Treatment Market Dynamics

Increasing incidence of neuroendocrine tumors

Insulinomas are neuroendocrine tumors leading to insulin hypersecretion and hypoglycemia. Incidence of NET has increased across the globe in past decades, predominantly gastrointestinal, pancreatic, and bronchial sites. These tumors are caused by various environmental factors which lead to gene mutations. The prevalence of insulinoma, a prominent type of neuroendocrine tumor, has been increasing in the past two years.  

The incidence of insulinoma is 1 to 4  per million per year. Insulinoma is a single benign tumor; in 5.8% of cases, it can be malignant. Over 87.5% of patients get cured (being free of symptoms for at least six months) after surgery. The majority of insulinoma are between 30-60 years of age, around 59% account for women. 

In March 2022, according to the American Society of Clinical Oncology, more than 12,000 people in the United States are diagnosed with neuroendocrine tumors annually. Approximately 171,000 people are living after the diagnosis of NET. 

According to Cancer Australia.gov, in 2022, the estimated number of new neuroendocrine tumors diagnosed is 5437, of which 2846 are males and the rest are females. Compared to 2018, the number of people diagnosed with NET kept increasing.

Furthermore, advancements in drug discoveries, increasing product launches, and rising awareness about diabetes, and hypoglycemia are a few factors which are expected to drive the market in the forthcoming period.

Adverse effects of somatostatin analogs

Somatostatin analogs are designed for anti-tumor activity and cause many adverse effects, such as steatorrhea, which can be controlled with medication. It causes occasional nausea, gastrointestinal cramps, and malabsorption. It mainly inhibits gall bladder contractions, which leads to gallstones. In 2023, according to the National Center for Biotechnology Information, nearly 27% of patients treated with Sandostatin developed gallstones.  

Insulinoma Treatment Market Segment Analysis

The global insulinoma treatment market is segmented based on disease type, treatment type, end user, and region.

The Somatostatin analogs segment accounted for approximately 46.2% of the market share 

Somatostatin analogs are used as a first-line treatment for neuroendocrine tumors. As these have anti-proliferative properties, these analogs are extensively used to treat neuroendocrine tumors. They are more potent when compared to other drugs as they block the activity of the tumor near the pancreas that is removed later by surgery. Currently, only two analogs are available for the treatment, and the others are still in the pipeline.  

In September 2023, Novartis declared a Phase III NETTER-2 trial with Lutathera. First-line treatment with Lutathera and long-acting octreotide significantly improved in patients with newly diagnosed somatostatin receptors. 

In October 2022,  ITM Isotope Technologies Munich SE, a biotechnology company, received Fastrack designation from the US Food and Drug Administration for  ITM-11 (edotreotide) for treating neuroendocrine tumors.

Global Insulinoma Treatment Market Geographical Share

North America accounted for approximately 41.3% of the market share in 2022

North America is expected to hold the largest market share due to the high rates of type 1 and type 2 diabetic individuals in the U.S. According to the diabetes journal organization, hypoglycemic individuals in the U.S. jumped 25% to 32% by 2019. Neuroendocrine tumors affect about 5 in 100,000 people. More than 12,000 new cases are diagnosed yearly, and as many as 125,000 people with these tumors live in the U.S.

Approximately 12,000 - 15,000 Canadians with NETs, only 10% get accurate diagnosis and treatment.  Nearly 552 Canadians with either type 1 or type 2 diabetes, almost two-thirds of total respondents reported experiencing at least one hypoglycemic event, such as insulinomas.

COVID-19 Impact Analysis

COVID-19 has had a very slight impact on the insulinoma treatment market. There is a halt in the supply chain of drugs due to the implementation of lockdowns worldwide. A shift in the focus of clinical trials was observed for developing vaccines and medicines. There is a decreased research and development in the oncology sector during COVID 19. Due to the fear of visiting the hospitals, the diagnosis and treatment were postponed and done later.

Insulinoma Treatment Market Companies

The major global players in the insulinoma treatment market include Baxter International Inc, Salvavidas, AdvaCare Pharma, Merck KGaA, Accord Healthcare US, Midas Pharma GmbH, Biosynth, Livealth, Ipsen Biopharmaceuticals, Inc., Cipla USA, Inc. among others.

Key Developments

• In August 2023, Exelixis, Inc. declared positive results from the phase 3 cabinet pivotal trial evaluating Cabozantinib in Advanced Pancreatic and Extra Pancreatic Neuroendocrine Tumors (pNET).
• In November 2022, Tetris Pharma, a subsidiary of Arecor Therapeutics, launched a prefilled auto-injector pen for hypoglycemia that is caused due to insulinoma in Germany which has been approved for the treatment of severe hypoglycemia in children and adults.

Why Purchase the Report?

• To visualize the global insulinoma treatment market segmentation based on disease type, treatment type, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of insulinoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global insulinoma treatment market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies